Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters











Publication year range
4.
Ann Surg Oncol ; 31(9): 6097-6117, 2024 Sep.
Article in English | MEDLINE | ID: mdl-38888862

ABSTRACT

INTRODUCTION: The worldwide incidence of melanoma has increased in the last 40 years. Our aim was to describe the clinic-pathological characteristics and outcomes of three cohorts of patients diagnosed with melanoma in a Latin-American cancer institute during the last 20 years. METHODS: We evaluated three retrospective patient cohorts diagnosed with melanoma at Instituto Nacional de Enfermedades Neoplasicas (INEN), a public hospital in Lima, Peru, for the years 2005-2006, 2010-2011, and 2017-2018. Survival rate differences were assessed using the Log-rank test. RESULTS: Overall, 584 patients were included (only trunk and extremities); 51% were male, the mean age was 61 (3-97) years, and 48% of patients resided in rural areas. The mean time to diagnosis was 22.6 months, and the mean Breslow thickness was 7.4 mm (T4). Lower extremity was the most common location (72%). A majority of the patients (55%) had metastases at the time of presentation, with 36% in stage III and 19% in stage IV. Cohorts were distributed as 2005-2006 (n = 171), 2010-2011 (n = 223), and 2017-2018 (n = 190). No immunotherapy was used. Cohort C exhibited the most significant increase in stage IV diagnoses (12.3%, 15.7%, 28.4%, respectively; p < 0.01). The median overall survival rates at the three-year follow-up demonstrated a decline over the years for stages II (97%, 98%, 57%, respectively; p < 0.05) and III (66%, 77%, 37%; p < 0.01). CONCLUSIONS: There has been a worsening in the incidence of late-stage metastatic melanoma in Peru throughout the years, coupled with a significant decline in overall survival rates. This is underscored by the fact that half of the population lives in regions devoid of oncological access.


Subject(s)
Melanoma , Skin Neoplasms , Humans , Melanoma/pathology , Melanoma/epidemiology , Melanoma/mortality , Male , Middle Aged , Female , Aged , Retrospective Studies , Survival Rate , Adult , Aged, 80 and over , Young Adult , Adolescent , Peru/epidemiology , Skin Neoplasms/pathology , Skin Neoplasms/epidemiology , Follow-Up Studies , Child , Child, Preschool , Prognosis , Incidence , Healthcare Disparities , Latin America/epidemiology
5.
Plast Reconstr Surg Glob Open ; 12(3): e5653, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38463701

ABSTRACT

Background: Tranexamic acid (TXA) has demonstrated promising outcomes in plastic surgery. Our aim was to assess the effect of TXA in intraoperative bleeding, operative time, and complications among patients undergoing facial surgical procedures. Methods: A retrospective cohort study of patients who underwent multiplane facial rhytidectomy from January 2018 to September 2022 at the Clinica Ziegler, Lima, Peru. Patients were divided into two groups according to the use of intravenous plus local infiltration of TXA. We performed the chi square test to assess associations among categorical variables, the Student t test and Mann-Whitney U test for categorical with continuous variables, and Pearson correlation for quantitative variables. Results: A total of 100 patients were included with 50 patients in each group. The median age was 59.5 years and the majority were women (88%). The median operative time was 288.5 minutes. The TXA group presented less intraoperative bleeding (40 versus 90 mL, P < 0.05) and shorter operative time (237 versus 353 minutes, P < 0.05); no differences in the development of hematoma (2% versus 12%, P = 0.11), less ecchymosis (2% versus 36%, P < 0.05), edema (2% versus 100%, P < 0.05), and time to drain removal (3 versus 6 days, P < 0.05). Conclusions: TXA improves the short- and long-term outcomes of patients who undergo multiplane facial rhytidectomy. It also decreases intraoperative bleeding by more than half and reduces the operative time by one third. Moreover, patients receiving TXA presented significantly less ecchymosis, edema, and time to drain removal.

6.
Plast Reconstr Surg Glob Open ; 12(1): e5520, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38204871

ABSTRACT

Breast-implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a non-Hodgkin lymphoma that arises in the space between the surface of a breast implant and the fibrous capsule that grows around the implant. Since its first description 20 years ago, almost 1000 cases of BIA-ALCL have been diagnosed worldwide. Nowadays, guidelines describe the diagnosis, staging, and treatment of this disease. We present the first two cases diagnosed and treated in Peru, demonstrating a wide range of aggressiveness of BIA-ALCL.

7.
Rev. senol. patol. mamar. (Ed. impr.) ; 36(4)oct.-dic. 2023. ilus
Article in Spanish | IBECS | ID: ibc-226742

ABSTRACT

La adenomatosis erosiva es una neoplasia benigna poco frecuente que afecta al pezón. Caracterizado por erosión, telorrea, telorragia, nodularidad, prurito y eritema, ocasionando un proceso destructivo progresivo del pezón, el cual puede ser confundido con la enfermedad de Paget; motivo por el cual el conocimiento de esta enfermedad es fundamental para evitar el sobretratamiento quirúrgico. Presentamos el caso de una paciente de 35 años diagnosticada y tratada con cirugía, así como la revisión de la literatura de esta entidad. (AU)


Erosive adenomatosis is a rare benign neoplasm that affects the nipple. Characterized by erosion, telorrhoea, telorrhagia, nodularity, pruritus and erythema, causing a progressive destructive process of the nipple, which can be confused with Paget's disease; which is why knowledge of this pathology is essential to avoid surgical overtreatment. We present the case of a 35-year-old patient diagnosed and treated with surgery, as well as a review of the literature on this entity. (AU)


Subject(s)
Humans , Female , Adult , Breast Neoplasms/surgery , Breast Neoplasms/pathology , Adenoma/surgery , Adenoma/pathology , Nipples
8.
Rev. senol. patol. mamar. (Ed. impr.) ; 36(1): 1-5, ene.-mar. 2023. ilus
Article in Spanish | IBECS | ID: ibc-215283

ABSTRACT

El tumor phyllodes representa el 1% de los tumores primarios de la mama, es una rara neoplasia fibroepitelial que tiene a la cirugía como piedra angular en el tratamiento: la resección con márgenes amplios (mayores o iguales a 1 cm) y la mastectomía son los tratamientos recomendados. Tomando en cuenta el impacto de los bordes quirúrgicos en la recurrencia local, el gran volumen de resección, la velocidad de crecimiento y la dificultad de predecir el comportamiento tumoral con el estudio preoperatorio de biopsia percutánea; la cirugía de conservación es un reto en muchos casos. Presentamos el caso de una paciente tratada con cirugía oncoplástica extrema, así como la revisión de la literatura de esta entidad. (AU)


The phyllodes tumor represents 1% of the primary tumors of the breast, it is a rare fibroepithelial neoplasia that has surgery as a cornerstone in the treatment: resection with wide margins (greater than or equal to 1 cm) and mastectomy are the recommended treatments; considering the impact of the surgical edges on local recurrence, the large resection volume, growth speed and the difficulty of predicting tumor behavior with the pre-operative percutaneous biopsy study; Conservation surgery is challenging in numerous instances. We present the case of a patient treated with extreme oncoplastic surgery, as well as a review of the literature on this entity. (AU)


Subject(s)
Humans , Female , Adult , Phyllodes Tumor/diagnostic imaging , Phyllodes Tumor/surgery , Breast
9.
Rev Fac Cien Med Univ Nac Cordoba ; 79(1): 53-56, 2022 03 07.
Article in English | MEDLINE | ID: mdl-35312250

ABSTRACT

INTRODUCTION: Cancer is the second leading cause of death worldwide, with 70% of cancer deaths occurring in low- or middle- income countries. To mitigate the mortality of this disease, it is recommended the evaluation of multiple high-penetrance genes. METHODS: We used a multi-gene panel testing to identify germline variants in a unique case of a breast cancer patient with a family history of five different neoplasm types. The patient, at the age of 50 years, was diagnosed with a high-grade cribriform ductal carcinoma in situ in her left breast. RESULTS: We identified two heterozygous mutations, one classified as pathogenic/likely pathogenic in RAD50 and the other classified as a variant of uncertain significance (VUS) in ATM. CONCLUSION: In conclusion, the use of the multi-gene panel leads to the identification of a double heterozygous mutation in RAD50 and ATM in a breast cancer patient from a Peruvian family with several cancer types. This data helps our physician team and the patient to choose a treatment following the post-test genetic counseling.


Subject(s)
Breast Neoplasms , Acid Anhydride Hydrolases/genetics , Ataxia Telangiectasia Mutated Proteins/genetics , Breast Neoplasms/diagnosis , Breast Neoplasms/genetics , DNA-Binding Proteins/genetics , Female , Genetic Counseling , Humans , Middle Aged , Mutation , Peru
SELECTION OF CITATIONS
SEARCH DETAIL